Crossref
What Does the EU HTA Regulation Mean for the Approval and Benefit Assessment of Neuropsychopharmaceuticals?
Psychopharmakotherapie · 2025
DOI: 10.52778/ppt20250021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmakotherapie, 2025. Verfasst von Karl Broich und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Broich, K., Haberkamp, M., Behring, A., Aislaitner, G., & Löbker, W. (2025). What Does the EU HTA Regulation Mean for the Approval and Benefit Assessment of Neuropsychopharmaceuticals?. Psychopharmakotherapie. https://doi.org/10.52778/ppt20250021
Vancouver
Broich K, Haberkamp M, Behring A, Aislaitner G, Löbker W. What Does the EU HTA Regulation Mean for the Approval and Benefit Assessment of Neuropsychopharmaceuticals?. Psychopharmakotherapie. 2025. doi:10.52778/ppt20250021
BibTeX
@article{Broich2025,
author = {Broich, Karl and Haberkamp, Marion and Behring, Antje and Aislaitner, Georgios and Löbker, Wiebke},
title = {What Does the EU HTA Regulation Mean for the Approval and Benefit Assessment of Neuropsychopharmaceuticals?},
journal = {Psychopharmakotherapie},
year = {2025},
doi = {10.52778/ppt20250021}
}
EUVIMED